In this episode of Curing with Sound, Lynn Dengel, MD, a surgical oncologist at UVA Health, discusses her groundbreaking clinical trial combining focused ultrasound with immunotherapy to treat patients with advanced melanoma. She shares insights into how this Foundation-funded trial – which is still enrolling patients – could help those who don’t benefit from standard immunotherapy alone.
Key points from the conversation:
- Melanoma is the most invasive type of skin cancer and accounts for the majority of skin cancer deaths. More than 100,000 Americans are diagnosed with melanoma each year.
- The study will enroll approximately 11 participants with advanced melanoma who are receiving a cancer immunotherapy drug (PD-1 antibody blockade) as part of their regular care and having the melanoma surgically removed.
- Dr. Dengel explains how focused ultrasound not only targets tumor tissue but may also create an enhanced environment for immunotherapy to work more effectively.
- As a senior advisor to the Foundation’s immunotherapy program, Dr. Dengel highlights the value of cross-institutional collaboration in advancing focused ultrasound research and improving patient outcomes.
UVA Health Study: Seeking Adult Patients with Advanced Melanoma Who are Receiving Immune Therapy and Who are Planning to Receive Surgery – MORE INFO
—————————-
QUESTIONS?
Email podcast@fusfoundation.org if you have a question or comment about the show, or if you would you like to connect about future guest appearances.
Email info@fusfoundation.org if you have questions about focused ultrasound or the Foundation.